Azafaros

Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar for the treatment of rare metabolic disorders including Lysosomal Storage Disorders. The lead candidate is designed to cross the blood-brain barrier and interfere with glycosphingolipid metabolism through a dual mode of action. The company targets patients with severe conditions such as GM2 gangliosidosis (Tay-Sachs disease) and other central nervous system-affecting metabolic pathways.